Publications
2026 (selected publications)
Detection of pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals.
Daniel K, Ullrich L, Ruchnewitz D, Meijers M, Halwe NJ, Wild U, Eberhardt J, Schön J, Stumpf R, Schlotz M, Wunsch M, Girao Lessa L, Abd El-Whab E-SM, Kuryshko M, Dietrich C, Pinger A, Schumacher A-L, Germer M, Rohde M, Kukat C, Gieselmann L, Gruell H, Hoffmann D, Beer M, Erren T, Lässig M, Kreer C, Klein F.
Immunity. 2026
read more
Identification of a broad and potent V3 glycan site bNAb targeting an N332gp120 glycan-independent epitope.
Gieselmann L, DeLaitsch AT, Rohde M, Radford C, Worczinski J, Momot A, Ahmadov E, Burger JA, Havenar-Daughton C, Deshpande S, Giovannoni F, Corti D, Kreer C, Ercanoglu MS, Schommers P, Georgiev IS, West AP Jr, Knüfer J, Stumpf R, Kroidl A, Geldmacher C, Maganga L, William W, Ntinginya NE, Hoelscher M, Yang Z, Wei Q, Renfrow M, Green TJ, Novak J, van Gils MJ, Gristick HB, Gruell H, Bloom JD, Seaman MS, Bjorkman PJ, Klein F.
Nat Immunol. 2026
read more
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation.
Gaebler C, Kor S, Allers K, Perotti M, Mwangi D, Meixenberger K, Hanke K, Trenkner T, Kraus T, Sha Y, Arentowicz C, Odidika S, Grahn N, Scheck R, Perkins N, Pardons M, Igbokwe V, Corman V, Burmeister T, Blau O, Sürücü G, Pruß A, Schneider CG, Klausen G, Sauter J, Klein F, Sander LE, Hofmann J, Vuong L, Bullinger L, Penter L, Gruell H, Reeves DB, Schommers P, Hoelzemer A, Obermeier M, Blau IW, Schneider T, Penack O.
Nature. 2026
read more
Complete list of publications
read more
2021 - 2025 (selected publications)
Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.
Gieselmann L, DeLaitsch AT, Rohde M, Gruell H, Kreer C, Ercanoglu MS, Gristick HB, Schommers P, Ahmadov E, Radford C, Mazzolini A, Zhang L, West AP, Worczinski J, Momot A, Reichwein ML, Knüfer J, Stumpf R, Mkhize NN, Kaldine H, Bhebhe S, Deshpande S, Giovannoni F, Stefanutti E, Benigni F, Havenar-Daughton C, Corti D, Kroidl A, Adhikari A, Nanfach AJ, Ambada GE, Duerr R, Maganga L, William W, Ntinginya NE, Wolf T, Geldmacher C, Hoelsche M, Lehmann C, Moore PL, Mora T, Walczak AM, Gilbert PB, Doria-Rose NA, Huang Y, Bloom JD, Seaman MS, Bjorkman PJ, Klein F.
Nat Immunol. (2025)
read more
Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies
Schultz EP, Ponsness L, Lanchy J-M, Zehner M, Klein F, Ryckman BJ.
Journal of Virology. (2025)
read more
SARS-CoV-2 Test-to-Stay in Daycare.
Dewald F, Steger G, Fish I, Torre-Lage I, Hellriegel C, Milz E, Kolb-Bastigkeit A, Heger E, Fries M, Buess M, Marizy N, Michaelis B, Suárez I, Rubio Quintanares GH, Pirkl M, Aigner A, Oberste M, Hellmich M, Wong A, Orduz JC, Fätkenheuer G, Dötsch J, Kossow A, Moench EM, Quade G, Neumann U, Kaiser R, Schranz M, Klein F.
Pediatrics. (2024)
read more
Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants.
Korenkov M, Zehner M, Cohen-Dvashi, Borenstein-Katz A, Kottege L, Janicki H, Vanshylla K, Weber T, Gruell H, Koch M, Diskin R, Kreer C, Klein F.
Immunity. (2023)
read more
Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool.
Weber T, Dähling S, Rose S, Affeldt P, Vanshylla K, Ullrich L, Gieselmann L, Teipel F, Gruell H, Di Cristanziano V, Kim DS, Georgiou G, Koch M, Kreer C, Klein F.
Sci Immunol. (2023)
read more
Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer.
Zehner M, Alt M, Ashurov M, Goldsmith JA, Spies R, Weiler N, Lerma J, Gieselmann L, Stöhr D, Gruell H, Schultz EP, Kreer C, Schlachter L, Janicki H, Laib Sampaio K, Stegmann C, Nemetchek MD, Dähling S, Ullrich L, Dittmer U, Witzke O, Koch M, Ryckman BJ, Lotfi R, McLellan JS, Krawczyk A, Sinzger C, Klein F.
Immunity. (2023)
read more
Dynamics and durability of HIV-1 neutralization are determined by viral replication.
Schommers P, Kim DS, Schlotz M, Kreer C, Eggeling R, Hake A, Stecher M, Park J, Radford CE, Dingens AS, Ercanoglu MS, Gruell H, Odidika S, Dahlhaus M, Gieselmann L, Ahmadov E, Lawong RY, Heger E, Knops E, Wyen C, Kümmerle T, Römer K, Scholten S, Wolf T, Stephan C, Suárez I, Raju N, Adhikari A, Esser S, Streeck H, Duerr R, Nanfack AJ, Zolla-Pazner S, Geldmacher C, Geisenberger O, Kroidl A, William W, Maganga L, Ntinginya NE, Georgiev IS, Vehreschild JJ, Hoelscher M, Fätkenheuer G, Lavinder JJ, Bloom JD, Seaman MS, Lehmann C, Pfeifer N, Georgiou G, Klein F.
Nat Med. (2023)
read more
Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals.
Kreer C, Lupo C, Ercanoglu MS, Gieselmann L, Spisak N, Grossbach J, Schlotz M, Schommers P, Gruell H, Dold L, Beyer A, Nourmohammad A, Mora T, Walczak AM, Klein F.
Nature Commun. (2023)
read more
Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa.
Simonis A*, Kreer C*, Albus A, Rox K, Yuan B, Holzmann D, Wilms JA, Zuber S, Kottege L, Winter S, Meyer M, Schmitt K, Gruell H, Theobald SJ, Helmman A, Meyer C, Ercanoglu MS, Cramer N, Munder A, Hallek M, Fätkenheuer G, Koch M, Seifert H, Rietschel E, Marlovits TC, van Koningsbruggen-Rietschel, Klein F*, Rybniker J*
Cell. (2023)
read more
Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning.
Radford CE, Schommers P, Gieselmann L, Crawford KHD, Dadonaite B, Yu TC, Dingens AS, Overbaugh J, Klein F, Bloom JD.
Cell Host Microbe. (2023)
read more
In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation.
Jensen BO, Knops E, Cords L, Lübke N, Salgado M, Busman-Sahay K, Estes JD, Huyveneers LEP, Perdomo-Celis F, Wittner M, Gálvez C, Mummert C, Passaes C, Eberhard JM, Münk C, Hauber I, Hauber J, Heger E, De Clercq J, Vandekerckhove L, Bergmann S, Dunay GA, Klein F, Häussinger D, Fischer JC, Nachtkamp K, Timm J, Kaiser R, Harrer T, Luedde T, Nijhuis M, Sáez-Cirión A, Schulze Zur Wiesch J, Wensing AMJ, Martinez-Picado J, Kobbe G.
Nat Med. (2023)
read more
Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients.
Dewald F, Pirkl M, Paluschinski M, Kühn J, Elsner C, Schulte B, Knüfer J, Ahmadov E, Schlotz M, Oral G, Bernhard M, Michael M, Luxenburger M, Andrée M, Hennies MT, Hafezi W, Müller MM, Kümpers P, Risse J, Kill C, Manegold RJ, von Frantzki U, Richter E, Emmert D, Monzon-Posadas WP, Gräff I, Kogej M, Büning A, Baum M, Teipel F, Mochtarzadeh B, Wolff M, Gruell H, Di Cristanziano V, Burst V, Streeck H, Dittmer U, Ludwig S, Timm J & Klein F.
Nat Commun. (2023)
read more
Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage.
Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Sander LE, Kurth F*, Klein F*.
Lancet Infect Dis. (2022)
read more
SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
Gruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, Münn F, Janicki H, Augustin M, Schommers P, Sander LE, Kurth F, Kreer C, Klein F.
Cell Host Microbe. (2022)
read more
Viral load dyamics in SARS-CoV-2 Omicron breakthrough infections.
Dewald F, Detmer S, Pirkl M, Hellmich M, Heger E, Herrmann M, Zweigner J, Klein F.
J Infect Dis. (2022)
read more
Effective high-throughput RT-qPCR screening for SARS-CoV-2 infections in children.
Dewald F, Suárez I, Johnen R, Grossbach J, Moran-Tovar R, Steger G, Joachim A, Rubio GH, Fries M, Behr F, Kley J, Lingnau A, Kretschmer A, Gude C, Baeza-Flores G, Del Valle DL, Roblero-Hernandez A, Magana-Cerino J, Hernandez AT, Ruiz-Quinones J, Schega K, Linne V, Junker L, Wunsch M, Heger E, Knops E, Di Cristanziano V, Meyer M, Hünseler C, Weber LT, Lüers JC, Quade G, Wisplinghoff H, Tiemann C, Zotz R, Jomaa H, Pranada A, Herzum I, Cullen P, Schmitz FJ, Philipsen P, Kirchner G, Knabbe C, Hellmich M, Buess M, Wolff A, Kossow A, Niessen J, Jeworutzki S, Schräpler JP, Lässig M, Dötsch J, Fätkenheuer G, Kaiser R, Beyer A, Rybniker J and Klein F.
Nature Communication. (2022)
read more
Antibody-mediated neutralization of SARS-CoV-2.
Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F.
Immunity. (2022)
read more
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.
Gruell H, Gunst JD, Cohen YZ, Pahus MH, Malin JJ, Platten M, Millard KG, Tolstrup M, Jones RB, Conce Alberto WD, Lorenzi JCC, Oliveira TY, Kümmerle T, Suarez I, Unson-O'Brien C, Nogueira L, Olesen R, Ostergaard L, Nielsen H, Lehmann C, Nussenzweig MC, Fätkenheuer G, Klein F, Caskey M, Sogaard OS.
Lancet Microbe. (2022)
read more
Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections.
Tober-Lau P, Gruell H, Vanshylla K, Koch WM, Hillus D, Schommers P, Suárez I, Suttorp N, Sander LE*, Klein F*, Kurth F*.
Emerg Infect Dis. (2022)
read more
Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals.
Poopalasingam N, Korenkov M, Ashurov A, Strobel J, Fish I, Hellmich M, Gruell H, Lehmann C, Heger E, Klein F.
J Clin Virol. (2022)
read more
Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults.
Vanshylla K, Tober-Lau P, Gruell H, Münn F, Eggeling R, Pfeifer N, Le NH, Landgraf I, Kurth F, Sander LE, Klein F.
Lancet Infect Dis. (2022)
read more
No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults.
Ercanoglu MS, Gieselmann L, Dähling S, Poopalasingam N, Detmer S, Koch M, Korenkov M, Halwe S, Klüver M, Di Cristanziano V, Janicki H, Schlotz M, Worczinski J, Gathof B, Gruell H, Zehner M, Becker S, Vanshylla K, Kreer C, Klein F.
iScience. (2022)
read more
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, Kurth F, Sander LE, Klein F.
Nature Medicine. (2022)
read more
Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization
Weber T, Potthoff J, Bizu S, Labuhn M, Dold L, Schoofs T, Horning M, Ercanoglu MS, Kreer C, Gieselmann L, Vanshylla K, Langhans B, Janicki H, Ströh LJ, Knops E, Nierhoff D, Spengler U, Kaiser R, Bjorkman PJ, Krey T, Bankwitz D, Pfeifer N, Pietschmann T, Flyak AI, Klein F.
Immunity. (2022)
read more
Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
Vanshylla K, Fan C, Wunsch M, Poopalasingam N, Meijers M, Kreer C, Kleipass F, Ruchnewitz D, Ercanoglu MS, Gruell H, Münn F, Pohl K, Janicki H, Nolden T, Bartl S, Stein SC, Augustin M, Dewald F, Gieselmann L, Schommers P, Schulz TF, Sander LE, Koch M, Łuksza M, Lässig M, Bjorkman PJ, Klein F.
Cell Host & Microbe. (2021)
read more
Safe and effective pool testing for SARS-CoV-2 detection
Wunsch M, Aschemeier D, Heger E, Ehrentraut D, Krüger J, Hufbauer M, Syed AS, Horemheb-Rubio G, Dewald F, Fish I, Schlotz M, Gruell H, Augustin M, Lehmann C, Kaiser R, Knops E, Silling S, Klein F.
J Clin Virol. (2021)
read more
Effective high-throughput isolation of fully human antibodies targeting infectious pathogens
Gieselmann L, Kreer C, Ercanoglu MS, Lehnen N, Zehner M, Schommers P, Potthoff J, Gruell H, Klein F.
Nature Protocols. (2021)
read more
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
Vanshylla K, Di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, Gruell H, Schlotz M, Ercanoglu MS, Stumpf R, Mayer P, Zehner M, Heger E, Johannis W, Horn C, Suárez I, Jung N, Salomon S, Eberhardt KA, Gathof B, Fätkenheuer G, Pfeifer N, Eggeling R, Augustin M, Lehmann C, Klein F.
Cell Host & Microbe. (2021)
read more
CD34T+ Humanized Mouse Model to Study Mucosal HIV-1 Transmission and Prevention
Vanshylla K, Held K, Eser TM, Gruell H, Kleipass F, Stumpf R, Jain K, Weiland D, Münch J, Grüttner B, Geldmacher C, Klein F.
Vaccines. (2021)
read more
Complete list of publications
read more
2016 - 2020 (selected publications)
Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer S, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F.
Cell. (2020)
read more
Antibody Teamwork against Ebola Virus Disease
Zehner M and Klein F.
Immunity. (2020)
read more
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
Schommers P, Gruell H, Abernathy ME, Tran M-K, Dingens AS, Gristick HB, Barnes CO, Schoofs T, Schlotz M, Vanshylla K, Kreer C, Weiland D, Holtick U, Scheid C, Valter MV, van Gils MJ, Sanders RW, Vehreschild JJ, Cornely OA, Lehmann C, Fätkenheuer G, Seaman MS, Bloom JD, Bjorkman J, Klein F.
Cell. (2020)
read more
OpenPrimeR for multiplex amplification of highly diverse templates
Kreer C, Döring M, Lehnen N, Ercanoglu MS, Gieselmann L, Luca D, Jain K, Schommers P, Pfeifer N, Klein F.
J Immunol Methods. (2020)
read more
Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies
Kreer C, Gruell H, Mora T, Walczak A.M. and Klein F.
Vaccines. (2020)
read more
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
Ehrhardt SA, Zehner M, Krähling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu MS, Schommers P, Gieselmann L, Eggeling R, Dahlke C, Wolf T, Pfeifer N, Addo MM, Diskin R, Becker S, Klein F.
Nat Med. (2019)
read more
Modeling the Amplification of Immunoglobulins through Machine Learning on Sequence-Specific Features.
Döring M, Kreer C, Lehnen N, Klein F, Pfeifer N.
Sci Rep. (2019)
read more
Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.
Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ.
Immunity. (2019)
read more
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.
Caskey M, Klein F, Nussenzweig MC.
Nat Med. (2019)
read more
Antibody-mediated prevention and treatment of HIV-1 infection.
Gruell H and Klein F.
Retrovirology. (2018)
read more
Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
Khera T, Behrendt P, Bankwitz D, Brown RJP, Todt D, Doepke M, Ghafoor Khan A, Schulze K, Law J, Logan M, Hockman D, Wong JAJ, Dold L, Gonzalez-Motos V, Spengler U, Viejo-Borbolla A, Ströh L, Krey T, Tarr AW, Steinmann E, Manns MP, Klein F, Guzman CA, Marcotrigiano J, Houghton M, Pietschmann T.
J Hepatol. (2018)
read more
Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption.
Lu CL, Pai JA, Nogueira L, Mendoza P, Gruell H, Oliveira TY, Barton J, Lorenzi JCC, Cohen YZ, Cohn LB, Klein F, Caskey M, Nussenzweig MC, Jankovic M.
PNAS. (2018)
read more
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Karagounis T, Cohen YZ, Wyen C, Scholten S, Handl L, Belblidia S, Dizon JP, Vehreschild JJ, Witmer-Pack M, Shimeliovich I, Jain K, Fiddike K, Seaton KE, Yates NL, Horowitz J, Gulick RM, Pfeifer N, Tomaras GD, Seaman MS, Fätkenheuer G, Caskey M, Klein F, Nussenzweig MC.
Nat Med. (2018)
read more
Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Lorenzi JCC, Cohen YZ, Wyen C, Kümmerle T, Karagounis T, Lu CL, Handl L, Unson-O'Brien C, Patel R, Ruping C, Schlotz M, Witmer-Pack M, Shimeliovich I, Kremer G, Thomas E, Seaton KE, Horowitz J, West AP Jr, Bjorkman PJ, Tomaras GD, Gulick RM, Pfeifer N, Fätkenheuer G, Seaman MS, Klein F, Caskey M, Nussenzweig MC.
Nature. (2018)
read more
LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model.
Meder L, König K, Dietlein F, Macheleidt I, Florin A, Ercanoglu MS, Rommerscheidt-Fuss U, Koker M, Schön G, Odenthal M, Klein F, Büttner R, Schulte JH, Heukamp LC, Ullrich RT.
Oncogene. (2018)
read more
Early antibody therapy can induce long-lasting immunity to SHIV.
Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M, Donau OK, Plishka RJ, Buckler-White A, Seaman MS, Lifson JD, Koup RA, Fauci AS, Nussenzweig MC, Martin MA.
Nature. (2017)
read more
Progress in HIV-1 antibody research using humanized mice.
Gruell H. and Klein F.
Curr Opin HIV AIDS. (2017)
read more
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.
Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY, Learn GH, Cohen YZ, Lehmann C, Gillor D, Shimeliovich I, Unson-O’Brien C, Weiland D, Robles A, Kümmerle T, Wyen C, Levin R, Witmer-Pack M, Eren K, Ignacio C, Kiss S, West AP, Mouquet H, Zingman BS, Gulick RM, Keler T, Bjorkman PJ, Seaman MS, Hahn BH, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC, Klein F.
Nat Med. (2017)
read more
Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.
Caskey M, Klein F, Nussenzweig MC.
N Engl J Med. (2016)
read more
Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4- binding site.
Gristick HB, von Boehmer L, West AP, Schamber M, Gazumyan A, Golijanin J, Seaman MS, Fätkenheuer G, Klein F, Nussenzweig MC, Bjorkman PJ.
Nat Struct Mol Biol. (2016)
read more
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T, Shimeliovich I, Patel R, Burke L, Cohen YZ, Hadrigan S, Settler A, Witmer-Pack M, West AP, Juelg B, Keler T, Hawthorne, T, Zingman B, Gulick RM, Pfeifer N, Learn GH, Seaman, MS, Bjorkman PJ, Klein F, Schlesinger SJ, Walker BD, Hahn BH, Nussenzweig MC.
Nature. (2016)
read more
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JC, Parrish EH, Learn GH, West AP Jr, Bjorkman PJ, Schlesinger SJ, Seaman MS, Czartoski J, McElrath MJ, Pfeifer N, Hahn BH, Caskey M, Nussenzweig MC.
Science. (2016)
read more
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.
Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K, Mankoff Z, Schmidt SD, Lifson JD, Mascola JR, Nussenzweig MC, Martin MA.
Nature. (2016)
read more
Complete list of publications
read more